OF COURSE Afrezza and Exubera are different, but the delivery method is THE issue with Afrezza from the CRL, is it not?
The delivery device was the problem with the Exubera experience/approach(IMO).
Fast Forward to 12/31/2011. 12/31/2011 Pfizer completes follow-on study of Exubera (will get good results IMO). (link to actual study in prior post)
12/31/2011 The Dreamboat Technosphere delivery device has been thoroughly vetted by the FDA. (link to actual study in prior post)
12/31/2011 Afrezza is approved for limited commercial use in Type I diabetic with no pulmonary issues and/or other conditions (COPD, etc); and remains limited until the 5-year comprehenive study of Afrezza (completed in 2013) is completed. Below is the link to the 5-yr study. http://clinicaltrials.gov/ct2/show/NCT00642616?term=mannkind&rank=6